Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulati...(ational salesorganizations. We look...)
| HOME >> BIOLOGY >> TECHNOLOGY |
ational sales organizations."
"We look forward to marketing InnerCool's products in Italy and are pleased to offer a comprehensive portfolio of temperature modulation systems to Italy's physicians and healthcare providers in this growing therapeutic market," stated Paolo Cremascoli, Chief Executive Officer of N.G.C. Medical. "The InnerCool product line is a good fit for our team since key clinicians and areas of the hospital where we focus are utilizing temperature modulation products and therapies."
InnerCool's Surface and Endovascular Temperature Modulation Systems
InnerCool's new CoolBlue(TM) surface temperature modulation system, which includes a console and a disposable CoolBlue vest with upper thigh pads, is designed to provide a tool for use in less acute patients or in clinical settings best suited to prolonged temperature management. InnerCool's CoolBlue vest and thigh pads wrap the body without requiring any adhesives to stick to the skin and produce cooling rates of around 1 degree Celsius per hour, i.e. similar to those of currently-marketed surface cooling systems and endovascular systems using inflatable balloon-based catheters. InnerCool's CoolBlue external or surface-based temperature modulation system is designed to cool or warm patients from outside of their bodies and is intended for use in less acute settings such as in-hospital fever management.
InnerCool's endovascular approach to patient temperature modulation is
based on a single-use flexible metallic catheter and a fully-integrated
cooling system, which allows for rapid and controlled cooling and
re-warming. InnerCool's endovascular system integrates a number of
desirable features including a slim catheter profile, a highly efficient
flexible metallic thermal transfer element, a built-in temperature
monitoring sensor, and a programmable console capable of rapidly and
controllably inducing, maintaining and reversing therapeutic cooling.
InnerCool's endovascular cat
'/>"/>
| SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
4. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
7. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
8. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
9. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
10. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
11. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |